ArticleNanomaterials (Basel, Switzerland)2020
Amphotericin B Loaded Polymeric Nanoparticles for Treatment of
Article in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 97 citations in OpenAlex.
- Central Nervous System Aspergillosis: Advances in Diagnosis, Therapeutics, and Multidisciplinary Management (2026 Update).Mycoses · 2026Review
- Kinetoplast-Directed Therapies: A Selective Mitochondrial Approach to Combat Leishmaniasis.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Surface-modified nanocarriers in the design of targeted drug delivery systems for parasitic diseases: a comprehensive review.BMC chemistry · 2026Review
- Drug Polymer Nanoparticles: An Advancement in Biomedical Solutions and Targeted Drug Delivery.Drug design, development and therapy · 2026Review
- Development of Novel Approaches for the Treatment of Cutaneous Candidiasis.Current pharmaceutical design · 2026Review
- Enhanced Skin Delivery of Amphotericin B: Development and Evaluation of Polymeric Nanoparticles Using a Porcine Ear Model.ACS omega · 2025Article
- Design, Synthesis, and Biological Evaluation ofMicroorganisms · 2025Article
- In Vitro Efficacy and Toxicity Assessment of an Amphotericin B Gel for the Treatment of Cutaneous Leishmaniasis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Amphotericin B Encapsulation in Polymeric Nanoparticles: Toxicity Insights via Cells and Zebrafish Embryo Testing.Pharmaceutics · 2025Article
- Itraconazole-Loaded Polycaprolactone Nanoparticle Gel for Enhanced Transdermal Delivery: Development, Characterization, and ex vivo Evaluation.International journal of nanomedicine · 2025Article
- Nanoparticles assisted intra and transdermic delivery of antifungal ointment: an updated review.Discover nano · 2024Review
- Microfluidic-Assisted Formulation of ε-Polycaprolactone Nanoparticles and Evaluation of Their Properties and In Vitro Cell Uptake.Polymers · 2023Article
- From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease.International journal of molecular sciences · 2023Review
- Vaterite microparticle-loaded methylene blue for photodynamic activity in macrophages infected with Leishmania braziliensis.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2023Article
- Emerging Polymer-Based Nanosystem Strategies in the Delivery of Antifungal Drugs.Pharmaceutics · 2023Review
- Terbinafine Nanohybrid: Proposing a Hydrogel Carrying Nanoparticles for Topical Release.Pharmaceutics · 2023Article
- Research progress of nanomaterial drug delivery in tumor targeted therapy.Frontiers in bioengineering and biotechnology · 2023Review
- Lipase-Responsive Amphotericin B Loaded PCL Nanoparticles for Antifungal Therapies.Nanomaterials (Basel, Switzerland) · 2022Article
- Design of double functionalized carbon nanotube for amphotericin B and genetic material delivery.Scientific reports · 2022Article
- pH Responsive Hydrogels for the Delivery of Capecitabine: Development, Optimization and Pharmacokinetic Studies.Gels (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections in immune-compromised patients are an important cause of mortality and morbidity. Amphotericin B (Amp B) is considered a powerful fungicidal drug but its clinical usage has certain limitations when administered intravenously due to its toxicity and poor solubility. In consideration of such challenges, in cutaneous leishmaniasis, the topical application of Amp B can be a safer option in many aspects. Thus, herein, biopolymer of polycaprolactone (PCL) nanoparticles (NPs) were developed with the loading of Amp B by nanoprecipitation for the treatment of topical leishmanial infections. Various parameters, such as concentration of PCL and surfactant Poloxamer 407, were varied in order to optimize the formation of nanoparticles for the loading of Amp B. The optimized formulation exhibited a mean hydrodynamic particle size of 183 nm with a spherical morphology and an encapsulation efficiency of 85%. The applications of various kinetic models reveal that drug release from nanoformulation follows Korsmeyer-Peppas kinetics and has a high diffusion exponent at a physiological pH of 7.4 as well a skin relevant pH = 5.5. The activity of the prepared nanoparticles was also demonstrated in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.